* A corporate client of Hybridan LLP ** Potential means Intention to Float (ITF) has been announced, or it is a rumour ***Arranged by type of listing and date of announcement ****Alphabetically arranged Share prices and market capitalisations taken from the current price on the day of publication Dish of the day Admissions: None Delistings: None What’s baking in the oven? Potential** Initial Public Offerings: Cardiogeni PLC has announced its intention to IPO on the AQS...
tatus of this Note and Disclaimer This document has been provided as a general market commentary and is issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as investment advice; a recommendation; an offer to sell; nor solicitation of any offer to buy any security or other financial instrument. Nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. The in...
24th July 2024 * A corporate client of Hybridan LLP ** Arranged by type of listing and date of announcement *** Alphabetically arranged **** Potential means Intention to Float (ITF) has been announced, or it is a rumour Dish of the day Admissions: None Delistings: None What’s baking in the oven? ** Potential**** Initial Public Offerings: ITF announced: 8th July 2024: Rome Resources: The Canada-based early-stage resource exploration Company has announced its intention to IPO on AIM in order to co...
4th June 2024 * A corporate client of Hybridan LLP ** Arranged by type of listing and date of announcement *** Alphabetically arranged **** Potential means Intention to Float (ITF) has been announced, or it is a rumour Dish of the day Admissions: Delistings: Apollon Formularies (AQSE:APOL) has withdrawn from the Aquis Stock Exchange What’s baking in the oven? ** Potential**** Initial Public Offerings: ITF announced: 22nd May: Raspberry Pi announces an intention to float onto the Premium listing ...
LendInvest continued to grow and gain market share in H1 of FY23 (to 30 Sep 22), with AUM closing on £2.43bn, 33% up y-o-y (30 Sep 21: £1.83bn) and 13% up over the half-year (31 Mar 22: £2.15bn). In the four years since the end of H1-19, when AUM stood at £546m, AUM has grown by a compounded annual growth rate of 45%. And despite a worsening macro-economic environment, half-year financial results were also solid. H1 revenue fell 8% y-o-y from £46.3m to £42.5m; adjusted EBITDA grew 7% from £13....
AUM ended H1 of FY23 (30 Sep 22) on £2.43bn, 33% up y-o-y (30 Sep 21: £1.83bn) and 13% up over the half-year (31 Mar 22: £2.15bn). While market data is not yet available to 30 Sep, it is obvious that LendInvest is continuing to rapidly gain market share. Lending products also continued to prove attractive to institutional investors. Funds under management (capital committed by investors) stood at £3.44bn on 30 Sep, up 17% over H1, which provides ample lending capital ‘headroom’ of £950m to fue...
LINV has delivered strong top-line growth with AUM up 36% to £2.1bn and revenue up 21% to £88m. But the standout feature of these results was operational gearing boosting profitability with adj. EBITDA jumping 90% to £20.3m and PAT up 187% to £10.9m. LINV is financially well-armed to pursue further growth with a strong balance sheet and ample lending capital from institutional investors. Indeed the Board has also recommended a maiden dividend of 4.4p per share: a sure sign of confidence in t...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.